Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

Notably, Janz and coworkers [ 20 ] observed YB-1 expression in 49% (20/42) of patients receiving chemotherapy, and there was a trend toward an association of YB-1 with poor disease-free survival, although this finding did not reach statistical significance.

also in 111,027 other papers